All In Biotech

Drug Trial Radar · NCT02752724

Ketamine Anesthesia for Improvement of Depression in ECT

Ketamine vs. Methohexital Anesthesia for Improvement of Major Depressive Disorder in Electroconvulsive Therapy

Last checked: Nov 20, 2026Latest source record: Jun 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Mar 2016

Primary completion

Apr 2017

Study completion Apr 30, 2018

Sponsor

Lead sponsor
VA Puget Sound Health Care SystemFederal agency
Sponsor type
Federal agency
First posted
Apr 27, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this prospective randomized clinical trial is to determine if patients receiving ketamine as a part of general anesthesia during electroconvulsive therapy (ECT) rather than standard of care will have improvement in symptoms of depression after a course of ECT treatments. The investigators hypothesize that utilization of ketamine for induction of general anesthesia during ECT treatments will improve symptoms of depression better than standard care. This study is ONLY open to patients eligible to receive healthcare services through the Department of Veterans Affairs at the VA Puget Sound, which means service in the active military, naval or air service or separation under any condition other than dishonorable. Qualifications for VA health care benefits can be found at va.gov.

Conditions

  • Major Depressive Disorder

Interventions

  • KetamineDrug

    Ketamine anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.

  • MethohexitalDrug

    Methohexital anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Depression Patient Health Questionnaire 9 (PHQ9) ScoringTime frame: Change from Baseline Score 24 hours prior to starting ECT to PHQ9 score 72 hours following last ECT session

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • VA Puget Sound Health Care System

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.